— Know what they know.
Not Investment Advice

APUS AMEX

Apimeds Pharmaceuticals US, Inc
1W: -2.8% 1M: +633.1% 3M: +234.6% YTD: +276.6% 1Y: +201.0%
$8.00
+1.71 (+27.19%)
 
Weekly Expected Move ±451.2%
$-45 $-20 $6 $31 $57
AMEX · Healthcare · Biotechnology · Alpha Radar Buy · Power 58 · $12.1M mcap · 563192 float · 34.05% daily turnover · Short 48% of daily vol
Smart Money Score
Watch 0
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$12.1M
52W Range5.44-59.7
Volume63,451
Avg Volume191,772
Beta-0.31
Dividend
Analyst Ratings
No analyst coverage
Company Info
CEOVinod Menon
Employees7
SectorHealthcare
IndustryBiotechnology
IPO Date2025-05-09
2 East Broad Street
Matawan, NJ 08525
US
808-209-7887
About Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.

Recent Insider Trades

NameTypeSharesPriceDate
Weintraub Bennett A-Award 10,000 $2.67 2025-11-11
Yoon Hankil A-Award 10,000 $2.67 2025-11-11
Koo Jakap A-Award 10,000 $2.67 2025-11-11
O'DONNELL CAROL A A-Award 10,000 $2.67 2025-11-11
Kogan Elona A-Award 10,000 $2.67 2025-11-11

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms